Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data
- PMID: 25459157
- DOI: 10.1016/j.oraloncology.2014.10.010
Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data
"V体育官网入口" Abstract
Targeted immunotherapy promoting anti-tumor T-cell activity has shown improved survival and durable objective responses in advanced melanoma patients. Data is mounting that concurrent use of ipilimumab and nivolumab has a more pronounced effect than either as monotherapy VSports手机版. Although no completed clinical trials exist for their use in head and neck cancer, preclinical data suggests these therapies would be beneficial in head and neck malignancies as well. Their role in head and neck cancer management is an ongoing research effort. .
Keywords: CTLA-4; Head and neck cancer; Immunotherapy; Ipilimumab; Nivolumab; PD-1 V体育安卓版. .
Copyright © 2014 Elsevier Ltd. All rights reserved. V体育ios版.
Publication types
- VSports - Actions
MeSH terms (VSports在线直播)
- "V体育2025版" Actions
- "VSports最新版本" Actions
- "VSports注册入口" Actions
- "V体育官网入口" Actions
- Actions (VSports)
- VSports手机版 - Actions
- V体育官网 - Actions
Substances
- Actions (VSports手机版)
- "V体育官网入口" Actions
- V体育2025版 - Actions
LinkOut - more resources (V体育安卓版)
- Full Text Sources
- Other Literature Sources
- Medical
 
        